Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

OLE Study to Evaluate Safety / Efficacy of ZD4522

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00654303
Recruitment Status : Completed
First Posted : April 7, 2008
Last Update Posted : March 16, 2009
Information provided by:

Brief Summary:
The purpose of this study is to assess the long term safety of Crestor.

Condition or disease Intervention/treatment Phase
Hypercholesterolaemia Drug: Rosuvastatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3500 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ZD4522 Long Term Extension Trial
Study Start Date : August 1999
Actual Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: Rosuvastatin
Other Name: Crestor

Primary Outcome Measures :
  1. Safety, as determined by adverse events, laboratory data, physical examination and ECG. [ Time Frame: 12 weekly ]

Secondary Outcome Measures :
  1. Success in achieving goals for Cholesterol levels [ Time Frame: 12 weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion of previous Crestor study as listed in the protocol.

Exclusion Criteria:

  • Pregnant or breast feeding women, or not using appropriate contraception.
  • Abnormal lab values as listed in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00654303

Sponsors and Collaborators
Layout table for investigator information
Study Director: Elinor Miller, MD AstraZeneca

Layout table for additonal information
Responsible Party: Elisabeth Björk, AstraZeneca Identifier: NCT00654303    
Other Study ID Numbers: 4522IL/0034
First Posted: April 7, 2008    Key Record Dates
Last Update Posted: March 16, 2009
Last Verified: March 2009
Keywords provided by AstraZeneca:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors